{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:47:56Z","timestamp":1780958876283,"version":"3.54.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:p>Background: Alzheimer\u2019s disease (AD) is a progressive neurodegenerative pathology that leads to cognitive decline and dementia, particularly in older adults. It disrupts brain structure and function, with neurotoxic amyloid-\u03b2 (A\u03b2) plaques being a primary pathological hallmark. Pharmacotherapeutic trials targeting A\u03b2 and other AD pathological features aim to slow disease progression. Functional magnetic resonance imaging (fMRI) is a non-invasive tool that visualizes brain functional activity, aiding in evaluating the efficacy of AD drugs in clinical trials. Objective: This mini-review explores the role of fMRI in evaluating the impact of AD pharmacotherapeutic clinical trials conducted in the past seven years. Methods: Literature was systematically searched using two databases. The risk of bias was assessed with the Revised Cochrane risk-of-bias tool (RoB-2) for randomized clinical trials (RCTs). Results: Four studies using fMRI to investigate AD drug efficacy were included. Cholinesterase, glutamatergic, and serotonergic drugs showed significant positive effects on brain functional activity, especially within the default mode network. Functional connectivity (FC) changes due to drug intake were linked to cerebellar and cholinergic decline in AD, correlating with improved global cognition and fMRI task performance. Conclusions: Recent RCTs demonstrate fMRI\u2019s ability to reveal longitudinal FC pattern changes in response to AD drug treatments across disease stages. Positive FC changes in distinct brain regions suggest potential compensatory mechanisms from drug intake. However, these drugs have limited efficacy, necessitating further research to enhance specific pharmacological interventions for clinical application.<\/jats:p>","DOI":"10.3233\/jad-231276","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T10:52:00Z","timestamp":1729248720000},"page":"S567-S578","source":"Crossref","is-referenced-by-count":1,"title":["Functional Magnetic Resonance Imaging in Alzheimer\u2019s Disease Drug Trials: A Mini-Review"],"prefix":"10.1177","volume":"101","author":[{"given":"Mohammed","family":"Alghamdi","sequence":"first","affiliation":[{"name":"Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, Australia"},{"name":"Department of Radiology and Medical Imaging, Faculty of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nady","family":"Braidy","sequence":"additional","affiliation":[{"name":"Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-231276_ref1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12916-014-0206-2","article-title":"The overlap between vascular disease and Alzheimer\u2019s disease-lessons from pathology","volume":"12","author":"Attems","year":"2014","journal-title":"BMC Med"},{"key":"10.3233\/JAD-231276_ref2","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/jnc.15471","article-title":"Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance","volume":"158","author":"Geula","year":"2021","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-231276_ref3","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.2147\/IJN.S200490","article-title":"Alzheimer\u2019s disease: Pathogenesis, diagnostics, and therapeutics","volume":"14","author":"Tiwari","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"10.3233\/JAD-231276_ref4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuroimage.2019.05.044","article-title":"Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer\u2019s disease","volume":"199","author":"Klaassens","year":"2019","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-231276_ref5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fneur.2020.00233","article-title":"The predicted key molecules, functions, and pathways that bridge mild cognitive impairment (MCI) and Alzheimer\u2019s disease (AD)","volume":"11","author":"Tao","year":"2020","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-231276_ref6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/msj.20157","article-title":"Neuropathology of Alzheimer\u2019s disease","volume":"77","author":"Perl","year":"2010","journal-title":"Mt Sinai J Med"},{"key":"10.3233\/JAD-231276_ref7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3390\/ph15121560","article-title":"Current pharmacotherapy and multi-target approaches for Alzheimer\u2019s disease","volume":"15","author":"Cheong","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.3233\/JAD-231276_ref8","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3389\/fneur.2019.01312","article-title":"New insights into the pathogenesis of Alzheimer\u2019s disease","volume":"10","author":"Fan","year":"2020","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-231276_ref9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/B978-0-12-802851-3.00006-1","article-title":"Chapter 6 - Apolipoprotein E and amyloid-\u03b2-independent mechanisms in Alzheimer\u2019s disease","author":"Kanekiyo","year":"2016","journal-title":"Genes, Environment and Alzheimer\u2019s Disease"},{"key":"10.3233\/JAD-231276_ref10","first-page":"e12063","article-title":"Nutritional status and structural brain changes in Alzheimer\u2019s disease: The NUDAD project","volume":"12","author":"Verhaar","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-231276_ref11","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-231276_ref12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/brain\/awx347","article-title":"Tau burden and the functional connectome in Alzheimer\u2019s disease and progressive supranuclear palsy","volume":"141","author":"Cope","year":"2018","journal-title":"Brain"},{"key":"10.3233\/JAD-231276_ref13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer\u2019s disease: Mechanisms and therapeutic strategies","volume":"15","author":"Gao","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-231276_ref14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neulet.2019.04.022","article-title":"The complexity of tau in Alzheimer\u2019s disease","volume":"705","author":"Naseri","year":"2019","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-231276_ref15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/187152710791012071","article-title":"Microglia and inflammation in Alzheimer\u2019s disease","volume":"9","author":"Mandrekar-Colucci","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.3233\/JAD-231276_ref16","doi-asserted-by":"crossref","first-page":"749587","DOI":"10.3389\/fncel.2021.749587","article-title":"Microglia in Alzheimer\u2019s disease: A target for therapeutic intervention","volume":"15","author":"Zhang","year":"2021","journal-title":"Front Cell Neurosci"},{"key":"10.3233\/JAD-231276_ref17","doi-asserted-by":"crossref","first-page":"102294","DOI":"10.1016\/j.ctim.2019.102294","article-title":"Oxidative stress in Alzheimer\u2019s disease: A review on emergent natural polyphenolic therapeutics","volume":"49","author":"Cassidy","year":"2020","journal-title":"Complement Ther Med"},{"key":"10.3233\/JAD-231276_ref18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer\u2019s disease in clinical trials","volume":"68","author":"Gody\u0144","year":"2016","journal-title":"Pharmacol Rep"},{"key":"10.3233\/JAD-231276_ref19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12916-019-1299-4","article-title":"ApoE4: An emerging therapeutic target for Alzheimer\u2019s disease","volume":"17","author":"Safieh","year":"2019","journal-title":"BMC Med"},{"key":"10.3233\/JAD-231276_ref20","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.bbadis.2015.12.016","article-title":"Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer\u2019s disease","volume":"1862","author":"Nelson","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-231276_ref21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jalz.2016.01.007","article-title":"Pathoconnectomics of cognitive impairment in small vessel disease: A systematic review","volume":"12","author":"Dey","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231276_ref22","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/030079905X56565","article-title":"Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer\u2019s disease over a 2-year period","volume":"21","author":"Bullock","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.3233\/JAD-231276_ref23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2019.00043","article-title":"The role of NMDA receptors in Alzheimer\u2019s disease","volume":"13","author":"Liu","year":"2019","journal-title":"Front Neurosci"},{"key":"10.3233\/JAD-231276_ref24","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer\u2019s disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol Sci"},{"key":"10.3233\/JAD-231276_ref25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jon.13063","article-title":"Functional magnetic resonance imaging, deep learning, and Alzheimer\u2019s disease: A systematic review","volume":"33","author":"Warren","year":"2023","journal-title":"J Neuroimaging"},{"key":"10.3233\/JAD-231276_ref26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1971400917697342","article-title":"Resting state fMRI: A review on methods in resting state connectivity analysis and resting state networks","volume":"30","author":"Smitha","year":"2017","journal-title":"Neuroradiol J"},{"key":"10.3233\/JAD-231276_ref27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3389\/fpsyg.2015.00663","article-title":"Reorganization of brain networks in aging: A review of functional connectivity studies","volume":"6","author":"Sala-Llonch","year":"2015","journal-title":"Front Psychol"},{"key":"10.3233\/JAD-231276_ref28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrn1246","article-title":"Alterations in the BOLD fMRI signal with ageing and disease: A challenge for neuroimaging","volume":"4","author":"D\u2019Esposito","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-231276_ref29","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1523\/JNEUROSCI.5062-08.2009","article-title":"Cortical hubs revealed by intrinsic functional connectivity: Mapping, assessment of stability, and relation to Alzheimer\u2019s disease","volume":"29","author":"Buckner","year":"2009","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-231276_ref30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euroneuro.2010.03.008","article-title":"Exploring the brain network: A review on resting-state fMRI functional connectivity","volume":"20","author":"Van Den Heuvel","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.3233\/JAD-231276_ref31","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.neurobiolaging.2011.09.009","article-title":"The potential of functional MRI as a biomarker in early Alzheimer\u2019s disease","volume":"32","author":"Sperling","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-231276_ref32","first-page":"e1","article-title":"Recent publications from the Alzheimer\u2019s Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials","volume":"13","author":"Weiner","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231276_ref33","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3233\/JAD-160537","article-title":"Staging Alzheimer\u2019s disease risk by sequencing brain function and structure, cerebrospinal fluid, and cognition biomarkers","volume":"54","author":"Chen","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-231276_ref34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11065-014-9249-6","article-title":"Functional brain connectivity using fMRI in aging and Alzheimer\u2019s disease","volume":"24","author":"Dennis","year":"2014","journal-title":"Neuropsychol Rev"},{"key":"10.3233\/JAD-231276_ref35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/agm2.12017","article-title":"Functional MRI technologies in the study of medication treatment effect on Alzheimer\u2019s disease","volume":"1","author":"Guo","year":"2018","journal-title":"Aging Med (Milton)"},{"key":"10.3233\/JAD-231276_ref36","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.euroneuro.2015.12.006","article-title":"Functional connectivity increase in the default-mode network of patients with Alzheimer\u2019s disease after long-term treatment with galantamine","volume":"26","author":"Blautzik","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.3233\/JAD-231276_ref37","unstructured":"Higgins JPT , Thomas J , Chandler J , Cumpston M , Li T , Page MJ , Welch VA (2024) Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024), Cochrane, 2024."},{"key":"10.3233\/JAD-231276_ref38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pscychresns.2016.01.018","article-title":"Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study","volume":"249","author":"Bokde","year":"2016","journal-title":"Psychiatry Res Neuroimaging"},{"key":"10.3233\/JAD-231276_ref39","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/ijnp\/pyab001","article-title":"Brain activity of benzoate, a D-amino acid oxidase inhibitor, in patients with mild cognitive impairment in a randomized, double-blind, placebo controlled clinical trial","volume":"24","author":"Lane","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.3233\/JAD-231276_ref40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2005.06.003","article-title":"Ways toward an early diagnosis in Alzheimer\u2019s disease: The Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)","volume":"1","author":"Mueller","year":"2005","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-231276_ref41","doi-asserted-by":"crossref","first-page":"22797","DOI":"10.1007\/s00521-021-06436-2","article-title":"Detection and classification of Alzheimer\u2019s disease from cognitive impairment with resting-state fMRI","volume":"35","author":"Buvaneswari","year":"2023","journal-title":"Neural Comput Appl"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-231276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:59:16Z","timestamp":1777370356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/JAD-231276"}},"subtitle":[],"editor":[{"given":"Paula I.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Jesus","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Daniela","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Miguel A.","family":"Pappolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Germ\u00e1n","family":"Plascencia-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Aaron A.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":41,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-231276","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}